A smarter Europe

IMMUNOCLUSTER-2

Introduction of a clinical study with an advanced cellular aHyC at interregional level

Duration

months

Start date

September 2023

End date

August 2025

Partner

Budget

749.059,60 €

ERDF Budget

599.247,68 €

Progress

The project

Project summary

Policy objective: PO1 - A more competitive and smarter Europe by promoting innovative and smart economic transformation and regional ICT connectivity

Specific objective: SO1 - Developing and enhancing research and innovation capacities and the uptake of advanced technologies

Typology: capitalization project

IIMMUNOCLUSTER-2 project addresses the strengthening of cross-border cooperation to improve the quality of life of the population.

Objectives

The general goal of the project is the initiation of a clinical trial for the treatment of triple negative breast cancer (TNBC) with a cell-based vaccine (aHyC) at the interregional level, to create the possibility of providing personalized advanced cancer therapies in an accessible and affordable way, to develop and improve innovation capabilities, and enabling the introduction of advanced technologies.
Considering the existing situation, the project will promote innovation and improve technology transfer to SMEs, strengthen cooperation between innovative companies, research and healthcare institutions, and allow the capitalization of the results achieved in the previous project INTERREG ITASLO 2014-2020 Immuno-Cluster in a new integrated framework at regional level.

Output

The main project outputs will be available soon.